4 transcripts
MIRM
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
. It facilitates the use and reimbursement of that product across the various settings where it's been established. So no major plans right now to focus
MIRM
Earnings call transcript
NASDAQ
2024 Q1
8 May 24
are progressing well. We continue to anticipate reimbursement and paid dispenses to materialize over the next few quarters.
Turning to CHOLBAM and CHENODAL
MIRM
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
to confirm that there would be no reimbursement or access impact on LIVMARLI in the EU?
Good question. At this point, we're focused on getting access
MIRM
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
in Germany and France launches, in line with what we saw in the U.S. launch of LIVMARLI. Pricing and reimbursement discussions are ongoing in major
- Prev
- 1
- Next